CME Group Inc. (CME) Stock Analysis
Is CME a good investment?
CME Group Inc. (CME) has a Plutrex AI rating of 68.5/100 as of October 05, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Unmatched profitability: 82.7% gross margin, 65.0% operating margin, 63.1% net margin — all dramatically above the industry average (28.1%, 52.5%, and 123% premiums respectively) — reflecting near-monopolistic exchange economics in U.S. interest rate and equity derivatives. Main concern: Structural growth deficit: next-year EPS growth of 5.58% is 79.8% below the industry average of 27.69%; revenue growth of 0.8% is essentially flat; PEG of 2.94 is 34% above peers — CME is more expensive per unit of growth than almost every competitor, making the current $263 price hard to justify on a growth-adjusted basis.
Investment Summary
CME Group is a world-class financial infrastructure business commanding extraordinary profitability — 82.7% gross margin, 65.0% operating margin, 63.1% net margin — that puts it in an elite tier among all large-cap companies. With a debt-to-equity of just 0.14 and $4.21B in annual free cash flow, the balance sheet is a fortress. However, the investment thesis is significantly constrained by a growth problem that cannot be ignored: next-year EPS growth of only 5.58% — 80% below the industry average of 27.69% — and flat revenue growth of 0.8% make CME a mature, utility-like business. The PEG ratio of 2.94 (34% above the industry average of 2.19) is the central valuation concern — investors are paying nearly 3x the growth rate for this earnings stream. News is broadly positive, with record September/Q3 ADV in interest rate and agricultural products, new Bitcoin futures contracts (benefiting from BitMEX's shutdown), and a growing S&P Dow Jones Indices income stream. But positive news merely supports the status quo and doesn't resolve the structural growth deficit. The analyst consensus target of $291.20 implies only 10.7% upside from current $263.14 — insufficient compensation for the valuation premium. This is a HOLD for existing shareholders collecting the special dividend, and a cautious entry for new buyers only at meaningful discount.
Key Strengths
- Unmatched profitability: 82.7% gross margin, 65.0% operating margin, 63.1% net margin — all dramatically above the industry average (28.1%, 52.5%, and 123% premiums respectively) — reflecting near-monopolistic exchange economics in U.S. interest rate and equity derivatives
- Fortress balance sheet with D/E of 0.14 (73.8% below industry average), $2.28B cash, and $4.21B annual FCF enabling consistent special dividends; record September/Q3 ADV in interest rate and agricultural products confirms durable volume growth in core franchises
- Competitive moat reinforced by news: BitMEX shutdown (headline: 'BitMEX shuts down after 11 years') redirects crypto derivatives flow toward regulated venues like CME, and new CME Bitcoin futures contracts capitalize on this structural shift — expanding into high-growth digital asset markets
Key Concerns
- Structural growth deficit: next-year EPS growth of 5.58% is 79.8% below the industry average of 27.69%; revenue growth of 0.8% is essentially flat; PEG of 2.94 is 34% above peers — CME is more expensive per unit of growth than almost every competitor, making the current $263 price hard to justify on a growth-adjusted basis
- Limited upside and valuation compression risk: analyst consensus target of $291.20 implies only 10.7% upside, while downside to a fair-value P/E of 15x on normalized earnings suggests $175–$210 fair value range — asymmetric risk/reward skewed to the downside for new buyers at current prices
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
CME's profitability is genuinely exceptional and industry-leading across every metric: gross margin 82.65% (vs. industry 64.54%), operating margin 65.04% (vs. industry 42.67%), net margin 63.11% (vs. industry 28.27% — a 123% premium). ROE of 15.8% is solid but modest given these margins, reflecting conservative leverage (D/E of 0.14 vs. industry 0.535). FCF of $4.21B annually underpins the dividend and special dividend program. The critical weakness is growth: revenue growth of 0.8% YoY (industry: 6.52%), historical earnings growth of 2.5% (industry: 20.02%), next-year EPS estimate of 5.58% (industry: 27.69%), and 5-year EPS CAGR of 7.6% (industry: 10.81%). CME lags peers on every single growth metric. The P/E of 22.32x is actually 11.5% below the industry average of 25.23x, which looks favorable in isolation — but the PEG of 2.94 (vs. industry 2.19) exposes that CME is more expensive on a growth-adjusted basis than its cheaper-looking multiple suggests. Intrinsic value on a 15x normalized earnings multiple applied to growth-adjusted earnings suggests fair value in the $175–$210 range, implying 20–33% downside risk from current prices. For income-oriented investors, the FCF yield of ~1.6% plus special dividends provides reasonable total return, but capital appreciation potential is limited at current valuations.
News Sentiment
CME Group is on a roll — and the numbers prove it. America's dominant derivatives exchange just reported record average daily trading volumes for both September and the entire third quarter, driven by surging demand for interest rate futures and record open interest in soybean contracts. Translation: more traders than ever are using CME's markets to hedge against economic uncertainty, and the company is cashing in. In the fast-moving world of crypto, CME is also seizing opportunity. When BitMEX — once one of the most powerful crypto exchanges in the world — shut its doors after 11 years, regulated platforms like CME stood to benefit. CME quickly announced new Bitcoin futures contracts, positioning itself to capture traders seeking safer, regulated venues for digital asset exposure. The company is also drawing attention from Wall Street analysts who are comparing CME head-to-head against Morningstar as a potential investment for 2026, highlighting its status as a premier financial infrastructure play. Behind the scenes, CME's stake in S&P Dow Jones Indices continues to quietly generate diversified income that many investors overlook. The big picture: CME remains one of the most profitable companies in America, with margins that most businesses can only dream of. The challenge? Growth is slow, and the stock isn't cheap. For patient, income-focused investors willing to wait for a better entry price, the fundamentals are compelling — but timing matters.
Risk Assessment
Primary risk: valuation compression if growth continues to disappoint — a PEG of 2.94 leaves little room for error; any earnings miss or volume slowdown in a low-volatility environment could trigger multiple contraction toward the 18–20x range, implying 10–20% downside from current levels. Secondary risk: CME's volume is cyclically tied to market volatility; prolonged low-volatility environments suppress ADV and revenue growth, reinforcing the flat growth narrative. Mitigation: CME's economic moat (near-monopoly in U.S. rate derivatives), special dividend program, and fortress balance sheet provide downside support — the stock is unlikely to collapse but may underperform the broader market at current valuations. Upside scenario: crypto derivatives expansion (Bitcoin futures), higher-volatility macro environment, or M&A driving growth acceleration could re-rate the stock toward analyst targets. Position sizing at 2.5% of portfolio reflects quality of business offset by valuation risk.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is CME a halal stock?
No, CME Group Inc. (CME) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for CME?
CME Group Inc. (CME) has a Plutrex AI rating of 68.5/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is CME a good investment?
According to Plutrex AI, CME has a Buy rating (68.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in CME?
US stocks like CME can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in CME?
Plutrex AI identifies the main risks for CME by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.